🔴 MBRX is trading 5% down today after disappointing trial results and Q1 earnings miss

MBRX is trading 5% down at $2.28 as investors react to disappointing interim cancer trial results and a significant Q1 2026 earnings miss.

• The stock has extended its multi-session slide after clinical data failed to reach statistical significance, fueling concerns over Moleculin Biotech’s pipeline prospects.
• A sizeable earnings miss has further pressured the company's financial trajectory, compounding negative sentiment alongside broader market weakness in U.S. equities.